M López

1.1k total citations
33 papers, 724 citations indexed

About

M López is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M López has authored 33 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in M López's work include Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Immunotherapy and Biomarkers (4 papers). M López is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Immunotherapy and Biomarkers (4 papers). M López collaborates with scholars based in Italy, United States and Spain. M López's co-authors include Patrizia Vici, G Paoletti, Luigi Di Lauro, Diana Giannarelli, Francesca Conti, Rosa Sciuto, C.L. Maini, J Coll, María Teresa Fernández‐Figueras and R. Cavaliere and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M López

33 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M López Italy 14 368 258 158 150 95 33 724
Francesca Simionato Italy 17 455 1.2× 199 0.8× 86 0.5× 290 1.9× 199 2.1× 31 794
Shigehiko Nishimura Japan 13 257 0.7× 128 0.5× 113 0.7× 182 1.2× 60 0.6× 50 617
Valeria Merz Italy 16 445 1.2× 179 0.7× 85 0.5× 353 2.4× 186 2.0× 36 851
Åse Bratland Norway 16 510 1.4× 263 1.0× 457 2.9× 277 1.8× 94 1.0× 43 1.0k
Sylvia Timme Germany 17 388 1.1× 133 0.5× 65 0.4× 369 2.5× 179 1.9× 37 795
Camilla Zecchetto Italy 12 417 1.1× 138 0.5× 85 0.5× 376 2.5× 196 2.1× 28 856
Xiaohong Yan United States 13 364 1.0× 157 0.6× 34 0.2× 233 1.6× 109 1.1× 50 610
Anne‐Claire Voegeli France 15 355 1.0× 462 1.8× 28 0.2× 305 2.0× 155 1.6× 25 772
Guido Giordano Italy 16 493 1.3× 179 0.7× 64 0.4× 267 1.8× 225 2.4× 76 916

Countries citing papers authored by M López

Since Specialization
Citations

This map shows the geographic impact of M López's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M López with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M López more than expected).

Fields of papers citing papers by M López

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M López. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M López. The network helps show where M López may publish in the future.

Co-authorship network of co-authors of M López

This figure shows the co-authorship network connecting the top 25 collaborators of M López. A scholar is included among the top collaborators of M López based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M López. M López is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Somaiah, Neeta, P Engstrom, Samuel Litwin, et al.. (2011). Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemotherapy and Pharmacology. 69(4). 977–982. 38 indexed citations
2.
Giacinti, Cristina, et al.. (2011). Scriptaid effects on breast cancer cell lines. Journal of Cellular Physiology. 227(10). 3426–3433. 26 indexed citations
3.
4.
Yan, Bing, Chao Gong, Zhen Yang, et al.. (2010). Neuropathology. Modern Pathology. 23. 375–382. 1 indexed citations
5.
Vici, Patrizia, Silvia Rossi, Claudio Botti, et al.. (2009). Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.. PubMed. 159(6). 453–6. 7 indexed citations
6.
Vici, Patrizia, Claudio Botti, Sabrina Rossi, et al.. (2009). Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.. PubMed. 159(6). 449–52. 4 indexed citations
7.
Maiello, Evaristo, Francesco Giuliani, Vittorio Gebbia, et al.. (2006). FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology. 17. vii55–vii59. 23 indexed citations
8.
Camps, Carlos, Bartomeu Massutí, I. Maestu, et al.. (2005). Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Annals of Oncology. 17(3). 467–472. 114 indexed citations
9.
Lauro, Luigi Di, Filiberto Belli, Maria Arena, et al.. (2005). Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Annals of Oncology. 16(9). 1498–1502. 12 indexed citations
10.
Maiello, Evaristo, Vittorio Gebbia, Francesco Giuliani, et al.. (2005). FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology. 16. iv56–iv60. 16 indexed citations
11.
Maiello, Evaristo, Vittorio Gebbia, Francesco Giuliani, et al.. (2000). 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Southern Italy Oncology Group. Annals of Oncology. 11(8). 1045–1052. 27 indexed citations
12.
Carpano, Silvia, Claudia Manfredi, Luigi Di Lauro, et al.. (1999). [Gemcitabine in advanced stage soft tissue sarcoma: a phase II study].. PubMed. 150(1). 17–20. 22 indexed citations
13.
López, M, Patrizia Vici, Francesca Conti, et al.. (1998). Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.. Journal of Clinical Oncology. 16(1). 86–92. 110 indexed citations
14.
Garaci, Enrico, M López, G Bonsignore, et al.. (1995). Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-αl and interferon-α2a. European Journal of Cancer. 31(13-14). 2403–2405. 36 indexed citations
15.
López, M, Patrizia Vici, Luigi Di Lauro, et al.. (1995). Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. European Journal of Cancer. 31(10). 1611–1614. 12 indexed citations
16.
Coll, J, et al.. (1995). Desmin myopathy: a multisystem disorder involving skeletal, cardiac, and smooth muscle. Human Pathology. 26(9). 1032–1037. 84 indexed citations
17.
López, M, Luigi Di Lauro, G Paoletti, et al.. (1995). Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects. Annals of Oncology. 6(10). 1011–1017. 13 indexed citations
18.
López, M, et al.. (1995). Giant cell myocarditis: Monocytic immunophenotype of giant cells in a case associated with ulcerative colitis. Human Pathology. 26(1). 121–123. 21 indexed citations
19.
López, M, Silvia Carpano, Patrizia Vici, et al.. (1995). CLINICAL MODULATION OF EPIRUBICIN RESISTANCE BY LONIDAMINE IN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS. International Journal of Oncology. 6(2). 363–7. 4 indexed citations
20.
López, M, Silvia Carpano, A Cancrini, et al.. (1993). Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma. Annals of Oncology. 4(8). 689–691. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Simionato Breakdown of academic impact, for papers by Shigehiko Nishimura Breakdown of academic impact, for papers by Valeria Merz Breakdown of academic impact, for papers by Åse Bratland Breakdown of academic impact, for papers by Sylvia Timme Breakdown of academic impact, for papers by Camilla Zecchetto Breakdown of academic impact, for papers by Xiaohong Yan Breakdown of academic impact, for papers by Anne‐Claire Voegeli Breakdown of academic impact, for papers by Guido Giordano
Rankless by CCL
2026